In Vitro Diagnostics Product Development Pipeline
Caprion was awarded a five-year, $12.9 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the US National Institutes of Health, to carry out research in the area of infectious diseases, which led to the creation of the Caprion Clinical Proteomic Center (CCPC ). The four programs performed by the CCPC focus on:
- Brucellosis, for the discovery and early stage validation of diagnostic as well as treatment monitoring biomarkers;
- Tuberculosis, for the discovery and early stage validation of diagnostic biomarkers for active tuberculosis;
- Avian flu vaccine, for the discovery and early stage validation of biomarkers predictive of response to a subunit H5N1 flu vaccine;
- Pediatric fever, for the discovery and early stage validation of biomarkers associated with unexplained acute febrile illness in children less than 5 years old, with particular emphasis on distinguishing malaria from acute lower respiratory infections
Diabetes and metabolic disease
Caprion was awarded a three-year, $2.3 million contract from the CQDM to for the discovery and early stage validation of biomarkers associated with diabetes disease progression as well as treatment monitoring.
In partnership with Takeda, San Francisco, Caprion is conducting a program aimed at identifying proteins secreted from visceral and abdominal fat that could serve as disease biomarkers.
Caprion is conducting a neuro-endocrine tumor program in partnership with Dr. Stephane Gasman from the l’Institut de Neurosciences Cellulaire et Integratives (INCI) in Strasbourg, France. This program, funded jointly by the CQDM and Alsace-BioValley at 1.1M CDN over 2 years, focuses on the discovery and early stage validation of diagnostic biomarkers and therapeutic candidates for neuro-endocrine cancers.